Using two complementary approaches based on transcriptional inactivation and peptide-based inhibition of FOXM1, we demonstrate the feasibility and efficacy of FOXM1 inhibition in ALL. This evidence concerns the gene FOXM1 and acute lymphoblastic leukemia.